Title: Metabolic effects of GH antagonism in patients with acromegaly
Abstract: Pegvisomant is a growth hormone (GH) receptor antagonist that represents a major advance in the treatment of acromegaly. Initial results with pegvisomant indicate this novel form of therapy to be the most effective treatment available for achieving biochemical disease control as ascertained by circulating IGF-I.
Publication Year: 2003
Publication Date: 2003-08-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot